SenesTech, Inc. (SNES)
0.829
-0.01
(-0.71%)
USD |
NASDAQ |
Oct 06, 16:00
0.83
0.00 (0.00%)
After-Hours: 20:00
SenesTech Gross Profit Margin (Quarterly) : 69.74% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 69.74% |
| March 31, 2026 | 62.47% |
| December 31, 2025 | 48.93% |
| September 30, 2025 | 59.28% |
| June 30, 2025 | 60.80% |
| March 31, 2025 | 57.94% |
| December 31, 2024 | 54.29% |
| September 30, 2024 | 56.64% |
| June 30, 2024 | 46.41% |
| March 31, 2024 | 23.61% |
| December 31, 2023 | 33.22% |
| September 30, 2023 | 39.17% |
| June 30, 2023 | 35.74% |
| March 31, 2023 | 24.03% |
| December 31, 2022 | 27.27% |
| September 30, 2022 | 34.80% |
| June 30, 2022 | 32.13% |
| March 31, 2022 | 12.31% |
| December 31, 2021 | 8.28% |
| Date | Value |
|---|---|
| September 30, 2021 | -0.55% |
| June 30, 2021 | -23.12% |
| March 31, 2021 | -39.77% |
| December 31, 2020 | -151.5% |
| September 30, 2020 | -45.45% |
| June 30, 2020 | -60.56% |
| March 31, 2020 | -167.6% |
| December 31, 2019 | -121.9% |
| September 30, 2019 | -250.0% |
| June 30, 2019 | -412.5% |
| March 31, 2019 | -547.4% |
| December 31, 2018 | -48.18% |
| September 30, 2018 | -111.4% |
| June 30, 2018 | -252.8% |
| March 31, 2018 | -615.8% |
| December 31, 2017 | -655.6% |
| September 30, 2017 | -658.8% |
| June 30, 2017 | -970.0% |
| March 31, 2017 | -800.0% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Enveric Biosciences, Inc. | -- |
| LENZ Therapeutics, Inc. | 94.90% |
| Impact BioMedical, Inc. | -9.40K% |
| ANI Pharmaceuticals, Inc. | 54.97% |
| Corcept Therapeutics, Inc. | 98.41% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -84.01% |
| Return on Assets | -59.99% |
| Return on Invested Capital | -63.72% |
| Profit Margin (Quarterly) | -237.9% |
| Operating Margin (Quarterly) | -241.8% |
| Return on Net Operating Assets | -164.3% |